投稿一覧に戻る
サンバイオ(株)【4592】の掲示板 2019/04/23〜2019/04/24
-
>>618
コロコロさん
ありがとうございます。
#588 は、日付を変えただけのようですね。
了解いたしました。 -
>>618
これさー完全に犯罪じゃね？今まで見てきてここまではっきりヤバイの初めてだわ。日付自分でわざわざ変えてフェイクニュース流したって事？PTSの株価の変化に影響あったぽくない？
ノラ (*'▽')
luckt
はぁ、、、
https://www.prnewswire.com/news-releases/sanbio-announces-fda-clearance-for-the-initiation-of-a-phase-i2a-clinical-trial-testing-their-cell-therapy-product-sb623-in-patients-with-traumatic-brain-injury-210850531.html
MOUNTAIN VIEW, Calif., June 10, 2013/PRNewswire/ -- SanBio Inc., a California-based regenerative medicine company, announced today that the U.S. Food and Drug Administration has approved their Investigational New Drug application (IND) for the use of SB623, a novel allogeneic stem cell therapy product, in patients suffering from traumatic brain injuries (TBI's). This approval allows the company to proceed with a Phase 1/2a clinical trial testing the safety and feasibility of the therapy. The clinical trial is expected to be carried out at several major hospitals in the United States.
"This is the second clinical program for SanBio," said Keita Mori, SanBio's Chief Executive Officer, "we see this as a clear validation of our development program and a significant broadening of the therapeutic application of our lead product SB623 for the treatment of unaddressed chronic neurological deficits."